We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Interaction of Cell Surface Glycoproteins Drives Tumor Metastasis

By LabMedica International staff writers
Posted on 16 Aug 2017
Cancer researchers have shown how the interaction between two classes of cell surface glycoprotein molecules determines when a tumor will metastasize and release cells that migrate and generate secondary growths.

Cells in a low-grade tumor bind very tightly together, however the cells become less adhesive as the tumor becomes malignant. More...
Expression of the cell adhesion molecule (CAM), Sialyl Lewis X (CD15s) correlates with cancer metastasis, while expression of E-selectin (CD62E) is stimulated by the cytokine TNF-alpha. CD15s/CD62E interaction plays a key role in the homing process of circulating leukocytes.

Investigators at the University of Portsmouth (United Kingdom) investigated the interaction of CD15s and CD62E in brain metastasis-related cancer cell adhesion. CD15s and CD62E were characterized in human brain endothelium (hCMEC/D3), primary non-small cell lung cancer (NSCLC), and metastatic NSCLC using immunocytochemistry, Western blotting, flow cytometry, and immunohistochemistry in human brain tissue sections.

They reported in the July 10, 2017, online edition of the International Journal of Molecular Sciences that CD15s was only faintly expressed on hCMEC/D3, while high levels were observed on primary NSCLC cells with expression highest on metastatic NSCLC cells. CD62E was highly expressed on hCMEC/D3 cells activated with TNF-alpha, with lower levels on primary and metastatic NSCLC cells. CD15s and CD62E were expressed on lung metastatic brain biopsies. CD15s/CD62E interaction was localized at adhesion sites of cancer cell - brain endothelium. Immune blocking of CD15s significantly decreased cancer cell adhesion to brain endothelium under static and shear stress conditions, highlighting the role of CD15s - CD62E interaction in brain metastasis.

Senior author Dr. Geoff Pilkington, head of the Brain Tumour Research Centre at the University of Portsmouth, said, "Although this work is still at an early stage, we have demonstrated key elements that are associated with tumor cell binding to blood vessels and this may provide a target for future drug development to prevent the development of secondary tumors in the brain. Increasing our understanding of the adhesive properties of tumors may also help to develop new treatments to halt the development and spread of primary brain tumors."

Related Links:
University of Portsmouth


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.